Vivax malaria: more severe and more resistant

Genton, Blaise and Mueller, Ivo. (2010) Vivax malaria: more severe and more resistant. Therapy, 7 (1). pp. 39-48.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A5843071

Downloads: Statistics Overview


The current dogma is that Plasmodium falciparum can lead to severe disease and death, whereas Plasmodium vivax is usually benign. Recent large prospective studies have demonstrated that P. vivax alone is associated with severe manifestations similar to those defining P. falciparum malaria. The proportion of severe malaria among P. vivax patients in Papua ranged from 3 to 23%, and the case-fatality rate from 0.8 to 1.6%. The prominent clinical features differ from site to site, severe anemia being the most common in Papua, respiratory distress in Papua New Guinea and hepatic failure and jaundice in India. This new paradigm is complicated by the spread of P. vivax resistance to chloroquine with rate of treatment failures as high as 50% in Indonesia and Papua New Guinea. Artemisinin-based combination therapies offer a good alternative to chloroquine, but further studies are needed to rationalize regimens containing both asexual and hypnozoite activity. The goal of malaria elimination will not be achieved without considering the specificities of P. vivax. New tools (drugs and vaccines) and innovative strategies to target the dormant forms of the parasites are required.
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Health Interventions > Malaria Interventions (Lengeler)
UniBasel Contributors:Genton, Blaise
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Future Medicine
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Last Modified:11 Feb 2019 15:34
Deposited On:14 Sep 2012 06:48

Repository Staff Only: item control page